Definition of idiotype
The term 'idiotype' (Id) refers to the entire repertoire of idiotopes found on a single immunoglobulin (Ig) molecule. Idiotopes are one of the two types of Ig antigenic determinants (or epitopes) identified by monoclonal antibodies (MoAb). As happens with allotopes, different individuals of the same species can recognize them as 'foreign'. However, there are crucial biological differences between idiotopes and allotopes. 1, 2 Allotopes are mostly located in the heavy and light chain constant region. They are recognized as foreign because of their presence on the Ig of the donor and their absence on that of the recipient. Furthermore, the differences between donor and recipient allotopes are of no functional significance. By contrast, idiotopes are mainly located in the hypervariable regions of the Ig variable domain, and are recognized as being foreign due to the fact that the tiny quantity present in any individual is insufficient to induce self-tolerance. Finally, the differences between donor and recipient idiotopes may be functionally relevant in the context of B cell function regulation.
Even though some seminal work on the anti-idiotypic immune responses had been performed earlier, it was in 1974 that a comprehensive hypothesis on the idiotypic network was formulated by Niels Jerne. 3 Jerne postulated that Id-specific antibodies can recognize their native target on the surface of B-lymphocytes and thereby influence the activation state of these cells either by stimulating or inhibiting them. Similarly, anti-Id T cells might recognize Id determinants, either in their entirety or as fragments, presented by the MHC molecules on
Basic principles of immunity to tumors
Isolation of tumor-specific antigens (TSAs) has been a long sought-after goal for scientists involved in both basic and clinical research. [4] [5] [6] Whereas tumor-associated antigens (TAAs) are localized on both normal and tumor cells, TSA are peculiar to tumor cells. This characteristic makes TSA a very desirable target for immune therapy strategies aiming to spare normal cells, or at least the indispensable ones. 2 As regards effector mechanisms, although some indirect evidence exists for participation of both natural killer (NK) cells (especially those activated by IL-2, known as lymphokineactivated killer, or LAK cells), and TNF-secreting macrophages in tumor immunity, most interest has been focused on the role of antigen-specific antibodies and T lymphocytes.
1 This is particularly true among scientists developing anti-Id vaccines for human FL, even though no substantial agreement has yet been reached on which of the two main effector pathways is most important. 7, 8 FL conforms to the general rule that tumors have several mechanisms to escape the attention of the immune system. 1, 2 The risk that Ig somatic hypermutations could result in aminoacid residue replacements leading to substantial changes within the fine immunogenic structure of the Id 9, 10 do not seem to be so relevant. Indeed, no such occurrence has been reported in any of the several dozen patients who have been immunized over the last decade. 11, 12 A much more relevant issue is the very limited ability of FL cells to present their own antigens. 13 Although ontogenetically very close to normal mature B-lymphocytes, with respect to their normal counterparts FL cells are very poor as antigen presenting cells (APCs). This makes it rather difficult to evaluate any vaccine-induced, tumor-specific cytotoxicity even in vitro. On the other hand, no such problems exist for ELISAbased detection of the tumor-specific and vaccine-induced humoral response.
The first study of anti-Id vaccinations in humans dates only from 1992.
14 Until then, all the work had obviously been confined to animal models. However, the accumulation of experimental data has led to the development of several promising strategies that are currently being investigated in clinical trials. These include the utilization of the Id in the form of a soluble protein or as a DNA sequence, either used to pulse dendritic cells (DCs) or else to be administered in combination with immunologic adjuvants.
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Historical perspective and rationale
Over the last decade, active immune therapy specific for human FL utilizing an anti-idiotype vaccine has gone from being a scientists' dream to the most refined form of active immune therapy currently to be found in the field of oncology.
The feasibility of exploiting the potential therapeutic value of a tumor's specific Ig, a TAA that also happens to be a TSA, was first demonstrated in animal models in the early 1970s. 17, 18 By the 1990s, the validity of this approach was being successfully studied in humans. Now, controlled clinical trials (particularly on FL) are starting to investigate whether immunizing cancer patients with an antigen derived from their own tumor can indeed provide an efficacious tool to help cure some cancer patients.
From the start, FL and MM were the clearest targets for an Id-based vaccine strategy. In MM, the antigen abundantly circulates in the bloodstream and therefore is very easily obtainable, [19] [20] [21] [22] [23] [24] whereas in FL the Ig is not secreted and therefore has to be isolated from the tumor cells themselves, which constitute its limited original source. However, serious practical considerations complicate the study of this approach in human MM, associated with the frequently severe clinical conditions of the patients who may have a substantial and binding need for conventional treatment. Despite the relative difficulty of obtaining the antigen in FL, the generally milder clinical conditions of the patients make this malignancy a somewhat easier terrain for clinical research into anti-Id vaccines. 25, 26 Furthermore, in contrast to B cell chronic lymphocytic or acute lymphobastic leukemias, which very seldom possess a conspicuous Ig-positive immunophenotype, FL consistently presents the antigen on the surface of its cells. 27 Another point in favor of FL is that, although incurable, this condition presents a long median survival regardless of the treatment chosen, if any at all. 28 This last feature, however, is a double-edged sword: it allows plenty of time to produce a labor-intensive, patient-and tumor-specific vaccine, but also means that a very long time will be required before any definitive conclusions can be drawn. 29 These factors underlie the pioneering work on the development of an anti-Id vaccine of three enterprising and tenacious scientists, namely Prof Levy at Stanford University, Prof Stevenson at Southampton University, and Dr Kwak at the National Cancer Institute (NCI) in Bethesda, whose unflagging dedication has allowed us to get to where we now stand.
As mentioned earlier, the entire anti-idiotypic approach stems from a simple idea: that the unique Ig synthesized by and found on neoplastic B cells also happens to be a TSA. This protein, which in some ways is rather like a monoclonal antibody (MoAb), has already failed to stimulate the host's immune system and to activate it against the tumor clone. The two main steps in an anti-Id vaccine strategy are firstly to obtain the purified TSA, and then to find a way of transforming it into an immunogen that is strong enough for therapeutic purposes. This second step is obviously quite different from the procedures used for the development of vaccines against infectious diseases, which are per se highly immunogenic and are designed for prophylactic administration.
Current strategies for the production of an anti-Id vaccine
The idiotypic vaccines currently available for clinical use in human FL belong to two distinct biochemical species: soluble proteins and DNA sequences. Although DNA sequences potentially offer considerable advantages, especially in terms of easier production of custom-made, patient-specific vaccines, their development is still in an early stage, and they have a long way to go before they can be tested in phase III clinical trials. On the other hand, soluble protein Id vaccines have now just entered this crucial phase, and it seems safe to state that the first clear indications as to whether this approach will indeed be able to produce real clinical benefits should be available by the end of this decade.
Soluble protein Id vaccine production is based on a hybridoma technique, 30 which in vitro allows production of exactly the same Ig as that present on the surface of the clonal B cells of FL, or in other words the tumor-specific Id. The suspension of single cells obtained from a biopsy specimen almost invariably contains a residual population of normal Blymphocytes alongside the tumor cells. Screening of the hybridomas by means of Ig heavy chain CDR3 PCR identification is therefore required in order to make sure that the Ig of the selected hybridoma is truly identical to the tumorassociated one. 31 Once the cultured hybridoma has yielded enough purified Id, the TSA needs to be made far more immunogenic than it is in its free form. For this purpose, it may either be conjugated with a highly immunogenic carrier such as keyhole limpet hemocyanin (KLH), 32 or else used to pulse autologous DCs. 33 The association of a soluble protein Id vaccine with immunologic adjuvants has also proved extremely important. Granulocyte-monocyte colony-stimulating factor (GM-CSF) currently seems to be the best such adjuvant both in animal models 34 and humans, 12 probably because of its capacity for local recruitment of DCs in vivo at the site of vaccine injections. 35, 36 This step would appear to be superfluous when autologous DCs are loaded with Id ex vivo and then re-injected into the patient.
A completely different alternative approach involves administration of the patient's Id-encoding DNA sequence. With the rise of molecular technology, such DNA vaccines are beginning to come into their own. 37 For instance, exploitation of appropriate molecular vectors (ie containing both a leader and promoter sequence) for insertion of the nucleotide sequences responsible for biosynthesis of both the Ig heavy and light chain's variable regions is now relatively easy. Between the heavy-and light-chain's variable regions' sequences, an intertwined linker peptide must also be inserted to allow the ultimate Id-containing molecule (scFv) to fold properly. 38 Furthermore, the vaccine can be further strengthened by adding other DNA sequences encoding for immunologic adjuvants or powerful immunogens to the vector. Finally, intramuscular injections allow progressive release of the Id following synthesis by muscular cells. In addition, this administration route seems to be associated with prolonged conservation of the genetic information within the cells without any apparent signs of integration into their genome. 39 
Studies in animal models
The first successful experimental Id vaccines followed on from studies on MOPC-315 mice in the early 1970s which showed that the idiotypic determinants contained within the clonal Ig synthesized by B cell cancers were unique and could therefore serve as TSAs. 17 Demonstration of the possibility of attaining substantial tumor protection by Id vaccination came shortly afterwards in the same mouse model. 18 Still in the 1970s, similar findings also emerged in other experimental models, such as 141 lymphoma, 40 MPC-11 myeloma, 41 L2C leukemia 42 and BCL1 lymphoma. 43 However, it was after development of a systematic approach to Id vaccination at Stanford University in the early 1980s that the evidence in favor of the strategy became overwhelming.
Firstly, a sound hybridoma technique was elaborated in order to reproduce the TSA in vitro, 44 an essential prerequisite for any controlled trials. It then emerged that conjugation of the Id with an immunogenic carrier was an essential step for significant tumor protection. 32 This paved the way for the use of KLH in almost all the ensuing stages of Id vaccine development. Finally, in the 1990s, two elegant experimental studies succeeded in showing that, among several candidates, GM-CSF seems to be the best available choice of immunological adjuvant. 32, 45 These concepts have now begun to be verified in humans. 12 The situation regarding Id DNA vaccines is somewhat less clear. Several investigators have successfully used this approach to induce both tumor-specific immune system activation and tumor protection in mice. [46] [47] [48] [49] However, these results have yet to be translated into potentially reliable clinical applications. Positive evidence of potential efficacy of this approach in humans will be required before the various intriguing methods that have been developed for rapid production of genetic Id vaccines, such as their expression in tobacco plants 50 or in E. coli, 51 can have a chance to pay off. In this regard, a major trial has just started at Southampton University to test one such vaccine in humans. The core of this vaccine consists of the patient's tumor-specific Id plus fragment C of the tetanus toxin. 39 Yet another strategy, which so far has only been tested in animal models, takes advantage of the so-called trioma-based vaccination in an attempt to bypass the problem of the low APC capacity of FL cells. 52, 53 The ultimate vaccine product is a bispecific MoAb, containing the lymphoma Id and the APCbinding arm, which redirects the Id to APCs. This approach is still in its infancy, and only time will tell whether it is actually feasible.
Soluble protein Id vaccines in clinical trials
Nearly 10 years have gone by since the first report of a phase I clinical trial on Id vaccine in human FL.
14 No more than 10 more years at the most should be necessary to get a clear indication as to whether Id vaccines really can cure at least some human FLs.
In 1992, Kwak et al 14 showed that in seven out of nine FL patients either in complete response (CR) or with evidence of persistent disease following chemotherapy, an Id vaccine was powerful enough to elicit an Id-specific immune response. In this work, the efficacy of the vaccine was demonstrated in terms of humoral response only, since the method utilized for evaluating the cellular response was not particularly reliable. In any case, this study provided the first formal proof that humans could be immunized against an antigen derived from their own tumor. Major features of this vaccine formulation included use of KLH as an immunological carrier for the Id, and of Syntex adjuvant formulation 1 (SAF-1) as an immunological adjuvant. 54 Although assessment of clinical benefit was outside the scope of this pioneering study, 14 these results paved the way for a whole series of phase II clinical trials.
Five years later, in 1997, Hsu et al 11 reported the long-term follow-up of 41 patients immunized at Stanford University. The results provided the first tentative evidence that the Id Leukemia vaccination might really be able to have an impact on the outcome of immunologically responsive patients. The patients had not been enrolled in a randomized trial and the groups were all very small. Nevertheless, many of the curves were rather striking. While all 41 patients vaccinated with their own tumor-specific Id-KLH combination displayed a specific immune response to KLH, 20 of them also showed an Idspecific immune response either in humoral or proliferative terms. However, no way was found for predicting candidates that are likely to develop an Id-specific response. Clinically, most of the patients vaccinated in CR who developed an Idspecific immune response obtained durable disease-free survival, whereas the majority of those who failed to develop any Id-specific response did not. Furthermore, the occasional tumor regressions achieved in patients who had evidence of disease seemed to depend on the presence of an Id-specific immune response. Comparison of the outcomes of immunologically responding patients with non-responding ones proved statistically significant both in terms of overall survival and freedom from progression (FFP) among patients vaccinated in first CR (P = 0.04 and P = 0.0001, respectively). The same could also be said for FFP both in those patients vaccinated without evidence of disease (P = 0.0377) and in those with evidence of disease (P = 0.0065). Overall, however, these results suggested that Id vaccination might be most beneficial for patients immunized in CR.
As for the formal demonstration of a tumor-specific cellular response based on cytotoxicity, preliminary data from Stanford University published at around the same time suggested that Id vaccination might be sufficiently powerful and specific to elicit induction of cytotoxic T lymphocyte (CTL) precursors. 55 However, it has now become clear that addition of GM-CSF to the vaccine formulation provides a practical way of augmenting tumor-specific CTL production. At the NCI, a phase II clinical trial has just been concluded 12 and the updated results were presented by Dr Kwak in the Workshop on Indolent Lymphoma held in Bologna in October 1999. 56 The 39 patients enrolled received uniform chemotherapy to be followed by Id-KLH vaccine plus GM-CSF 6 months after achieving continuous CR. Of the 25 patients who actually obtained CR, one relapsed within 6 months and two were never immunized due to technical problems in producing the custom-made vaccine. The current clinical data are still preliminary, but it is remarkable that with a follow-up ranging between about 3 and 6 years, 19 of the 22 vaccinated patients are still in continuous CR. Cellular and humoral vaccineinduced immune responses have been documented in vitro in 19/22 and 16/22 patients, respectively. Moreover, all these responses were specific both for the tumor and Id. However, the most exciting finding to come out of this study, was the formal demonstration in nine of 12 patients of vaccineinduced, sustained molecular remissions, as evaluated by PCR-based, t(14;18)-associated, bcl-2 rearrangement monitoring. This indirect evidence for Id-vaccine antitumor activity has now led to the start of the first phase III clinical trial aimed at assessing clinical benefits in a randomized setting.
Id-pulsed DCs in clinical trials
The idea of exploiting autologous DCs in the context of active immune therapy is not confined to the field of Id vaccines. 57 However, since several methods exist for obtaining DCs that are viable for both in vitro and ex vivo use, 58 it is not surprising that the soluble protein Id was first used to pulse these Leukemia professional APCs. The first report 59 on this strategy dates from 1996, when three out of four patients immunized at Stanford with Id-pulsed autologous DCs showed clear evidence of vaccine-induced, tumor-specific cellular immune response, albeit in the absence of any concomitant activation of the humoral arm of the immune system. These preliminary results have been recently updated at the 41st ASH Annual Meeting:
60 cellular immune response has been documented in 8/10 (80%) patients treated after relapse, and in 8/16 (50%) patients vaccinated in first CR, two (12.5%) of whom have achieved vaccine-induced molecular remissions. These results seem to provide indirect confirmation that Id-pulsed autologous DCs are capable of presenting Id epitopes associated with their surface HLA molecules in a way that elicits tumor-specific T cell activation.
Data were also presented at the 41st ASH Annual Meeting on the possibility of inducing a synergistic Id-vaccine effect by sequential administration of Id-pulsed DCs and soluble protein Id in order to try to activate both immune response arms. 61 Of the five currently evaluable patients, most are described as having developed both humoral and cellular immune responses. Once again, the number of patients is still too small and the follow-up too short to allow any conclusion to be drawn regarding the strategy's real clinical potential.
It will be interesting to see which of these competing strategies (Id-KLH + GM-CSF, Id-pulsed DCs, or a combination of the two) will ultimately prove superior. The cross-over from basic research to clinical trials has already been reached, and we should shortly be getting a clearer idea of which lines are most worth pursuing in terms of the actual benefits to FL patients.
DNA vaccines in clinical trials
A great deal of work on Id DNA vaccines in mice has provided a sound rationale for clinical applications. Very little evidence of antitumor activity is yet available in FL patients, but this is largely because the only phase I clinical trial conducted was designed merely to test safety and feasibility: the seven patients with end-stage disease immunized with a simple Id DNA scFv vaccine had little if any chance of developing an Id-specific immune response. 62 More exciting results could hopefully come from a recently started clinical trial that aims to recruit 30 FL patients in first CR. These patients will receive vaccination with escalating doses from 0.5 to 2.4 mg of DNA encoding each patient's scFv, fused to the tetanus toxin fragment C. Apart from confirming the substantial lack of toxicity seen in the previous trial, the major aims of the study are detection of humoral and cellular immune responses against both fragment C and the patients' tumor-specific Id protein. 39, 48 Looking to the future At least five Id vaccine clinical trials are currently underway around the world. First and foremost is the first phase III trial that is being conducted at the NCI. The formal inclusion of active immune therapy among the treatment options for human FL may depend on the outcome of this study. Two ongoing phase II trials at the Universities of Stanford and Yale regarding Id-pulsed, DC-based vaccines may also have important consequences, especially if this approach turns out to be potentially more effective than that based on the KLHconjugated soluble protein in association with GM-CSF. Otherwise, the soluble protein Id vaccine could become the gold standard, admittedly perhaps with the addition of superior immunological adjuvants. Another phase II clinical trial has just begun in Bologna to test on FL patients in second CR the Id-KLH + GM-CSF vaccine formulation that was used in the earlier NCI trial. If this study indicates that patients who have already relapsed after innovative but more conventional forms of treatment consistently respond to Id vaccination, this could provide important clues as to the best timing for vaccination within a global therapeutic strategy for FL patients. Indeed, the encouraging clinical data on the use of new drugs 63 and other biologic therapies in human FL [64] [65] [66] suggest the possibility of reserving the use of the Id vaccination approach for patients who prove refractory to other less costly and labor-intensive therapeutic options. Finally, another phase II clinical trial has recently started at the University of Southampton, focusing on Id DNA vaccines. This is welcome from the point of view of both clinical and basic research. Given the continuous expansion and refinement of molecular technologies, if Id DNA vaccines ultimately prove efficacious, their benefits might spread to the entire field of oncology.
A major issue that still requires serious consideration is the relationship between the assessment of vaccine-induced, Idand tumor-specific immune responses and actual clinical outcome. The correspondence between these two factors remains to be better defined, irrespective of whether clinical or molecular CR is chosen as the clinical end point. 12 Another highly controversial issue regards which type of immune response (ie humoral and/or cellular) has the highest clinical potential. There seems to be unanimous agreement that the ultimate goal should be the activation of both arms of the immune system. However, there are still two distinct schools of thought as to which one is more clinically decisive. 7, 67 Strictly related to this issue is the problem of how to harmonize the methods currently used to monitor specific cellular immune responses. None of the existing techniques is anywhere near as reliable as the ELISA method of measuring Idspecific humoral responses in vaccinated patients. So far proliferative tests, 11 cytokine secretion measurements 12 and CTL assays 12 have all been utilized with variable success. Although the gold standard should theoretically be set by some form of CTL assay, in practice the work of refining it has proved particularly difficult, probably due to the poor ability of FL cells to function as APCs. This fact has forced researchers to explore artificial ways of demonstrating vaccine-elicited CTL activity. One such approach involves preculturing naive autologous tumor cells with CD40 ligand-transfected fibroblasts 68 in order to stimulate in vitro immune T cells obtained from vaccinated patients prior to the CTL assay. It is clear that, even though specific activation of CTLs can be revealed in this way, what actually happens, or may happen, in vivo remains a matter of speculation.
Another important factor is time. Production of an Id vaccine for human FL currently takes months rather than weeks. Costs are high and any demonstration of a curative effect will inevitably be lengthy. Even so, the difficulty of the quest to discover a cure for FL makes this tumor type a front-line target for Id vaccine research. Despite the hot competition facing the Id vaccination strategy from new drugs and sophisticated passive immune therapy applications, the potential of this approach continues to fascinate both biologists and clinicians. The crucial question is how to target many if not all the antigenic determinants of a TSA, 69 rather than just one as in the case of monoclonal antibodies, while sparing normal cells as opposed to chemotherapy agents. The goal is an ambitious one, requiring the expenditure of a proportionate amount of effort.
Finally, much debate already surrounds the real significance of molecular and/or clinical CR in FL. The long-term implications of these responses (particularly of molecular remission) remain unclear. 70, 71 Most data seem to support the concept that when tumor-specific vaccination is performed during clinical CR, patients who develop a specific immune response tend to fare better than those who do not. 11, 12 However, the very few data currently available seem to suggest that the same may also be true for patients who receive the vaccine at a time when disease is clinically evident. 11 Since randomized studies have yet to be completed, no objective conclusions can be drawn in clinical terms. Nevertheless, the feeling is that: (1) The best clinical setting for Id vaccination is a durable, chemotherapy-induced clinical CR. 39 (2) Soluble protein Id vaccines are currently closer to demonstrating clinical benefit with respect to other possible formulations.
12 (3) Patients who develop an immune response following Id vaccination seem to obtain a more durable relapse-free survival, 11 even though no formal proof of this is yet available.
Concluding remarks
Many problems regarding anti-Id vaccines for human FL have already been successfully resolved. The trouble is that almost every solution seems to introduce a fresh problem that needs to be confronted. Despite this, the number of clinical trials in the field is constantly increasing, along with the number of researchers involved. This seems to be the best acknowledgement of the work of the renowned researchers mentioned above. Indeed, despite the substantial lack of internal competition, all the main avenues being explored appear to be capable of leading to valid results. The current situation also represents a major challenge. The specific features of both FL and Id vaccination make it difficult to provide clear answers as to which formulation, overall strategy and perhaps even timescale stand to benefit patients most.
Crucial questions still awaiting an answer include: do Id vaccines actually cure at least a fraction of FL patients? What is the most effective vaccine formulation? Is it possible to reduce the workload involved in producing an effective Id vaccine? These questions leave us with plenty of exciting challenges for the new decade.
